Adempas

Nazione: Nuova Zelanda

Lingua: inglese

Fonte: Medsafe (Medicines Safety Authority)

Principio attivo:

Riociguat 1mg

Commercializzato da:

Bayer New Zealand Limited

INN (Nome Internazionale):

Riociguat 1 mg

Dosaggio:

1 mg

Forma farmaceutica:

Film coated tablet

Composizione:

Active: Riociguat 1mg Excipient: Crospovidone Hyprolose Hypromellose   Iron oxide yellow Lactose monohydrate Magnesium stearate Microcrystalline cellulose Propylene glycol Purified water Sodium laurilsulfate Titanium dioxide

Tipo di ricetta:

Prescription

Prodotto da:

Bayer AG

Indicazioni terapeutiche:

Pulmonary arterial hypertension Adempas, as monotherapy or in combination with approved PAH treatments (endothelin receptor agonists or inhaled or subcutaneous prostanoids ), is indicated for the treatment of: - idiopathic pulmonary arterial hypertension - heritable pulmonary arterial hypertension - pulmonary arterial hypertension associated with connective tissue diseases - pulmonary arterial hypertension associated with congenital heart disease in adult patients with WHO functional Class II, III or IV symptoms.

Dettagli prodotto:

Package - Contents - Shelf Life: Blister pack, PP/Al - 42 tablets - 36 months from date of manufacture stored at or below 30°C - Blister pack, PP/Al - 84 tablets - 36 months from date of manufacture stored at or below 30°C

Data dell'autorizzazione:

2014-06-25